tbuckley/cabot-search huggingface dataset:
Abstract P4-01-07: Evaluation of FLT PET-CT as an imaging biomarker of proliferation in primary breast cancer
Authors: DK Woolf, M Beresford, SP Li, B Sanghera, WL Wong, V Amin, M-L Ah-See, D Miles, L Sonoda, S Detre, M Dowsett, A Makris
Journal: Cancer Research (2013)

Abstract Background [18F]flurothymidine (FLT) is proposed as an positron emission tomography (PET) imaging biomarker of proliferation for breast cancer. The aim of this prospective study was to assess the feasibility of FLT PET-CT as a technique for predicting response to neoadjuvant chemotherapy (NAC) in operable breast cancer and to compare baseline FLT to Ki-67. Methods 20 patients with primary breast cancer were recruited into this study and 19 received NAC with FEC (n = 6) or FEC-T (n = 13). A baseline FLT PET-CT scan was performed and repeated before the second cycle of chemotherapy. Expression of Ki-67 in the diagnostic biopsy was quantified after being stained by Dako Ki67 MIB-1 antibody and% positive cells scored. From the FLT PET-CT scans standardized uptake value maximum (SUVmax) were calculated. Results All 20 patients completed the baseline scan and 17 completed the second scan. Baseline Ki-67 results were available for 19 patients. Median age was 52 years (range 32 to 67), 12 patients were ER/ PR +ve, 6 Her-2 +ve and 6 triple negative. Mean baseline SUVmax was 7.3 (range 2.92 to 13.87) and 4.62 (range 1.79 to 14.15) post 1 cycle of NAC (range 7 to 14 days), representing a drop of 2.68 (36.3%). Mean baseline Ki-67 was 32.23 (range 2.3 to 68.4). Pearsons correlation showed a significant correlation between pre-chemotherapy Ki-67 and SUVmax of 0.604 (p = 0.006). 7 out of 17 (41%) patients achieved near pCR or pCR (pathological responders) after NAC and all of these had a reduction in SUVmax with a mean percentage value of –36.5% (range -0.5% to -62.5%). 10 out of 17 (59%) patients were non-responders and 8 of these had a reduction in SUVmax with a mean percentage value of -36.2% (range 11.3% to -70.7). Conclusions Baseline SUVmax measurements of FLT PET-CT were significantly related to Ki-67 suggesting that it is a proliferation biomarker. However, in this series neither the baseline value or the change in SUVmax after one cycle of NAC were able to predict response as most patients had a sizeable SUVmax reduction. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-07.
Aging, Immunity, and Infection
Authors: Laura Haynes
Journal: Annals of Internal Medicine (2003)

Medical Writings: Book Notes7 October 2003Aging, Immunity, and InfectionLaura Haynes, PhDLaura Haynes, PhDFrom The Trudeau Institute, Saranac Lake, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-7-200310070-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Albright JF and Albright JW. 256 pages. Totowa, NJ: Humana Pr; 2003. $99.50. ISBN 0896036448. Order phone 973-256-1699.Field of medicine: Gerontology, infectious diseases, and microbiology.Format: Hardcover book.Audience: Immunologists and clinicians interested in the effect of aging on infections and immune responses; researchers who need background information with good references of published studies.Purpose: To examine several aspects of infection and the decline of immunity with age.Content: The book contains 5 chapters. The first 4 discuss demographics and disease related to human aging and age-related effects on innate immunity and adaptive immunity, focusing on host-pathogen interactions. The ... Author, Article, and Disclosure InformationAffiliations: From The Trudeau Institute, Saranac Lake, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 October 2003Volume 139, Issue 7Page: 606KeywordsAgingImmune responseImmunityImmunologyImmunopathologyInfectious diseasesInformation technologyLife expectancyMicrobiologySoftware tools ePublished: 7 October 2003 Issue Published: 7 October 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effects of Lifestyle Activity vs Structured Aerobic Exercise in Obese Women&lt;SUBTITLE&gt;A Randomized Trial&lt;/SUBTITLE&gt;
Authors: Ross E. Andersen
Journal: JAMA (1999)

Physical inactivity contributes to weight gain, but only 22% of Americans are regularly active.To examine short- and long-term changes in weight, body composition, and cardiovascular risk profiles produced by diet combined with either structured aerobic exercise or moderate-intensity lifestyle activity.Sixteen-week randomized controlled trial with 1-year follow-up, conducted from August 1995 to December 1996.Forty obese women (mean body mass index [weight in kilograms divided by the square of height in meters], 32.9 kg/m2; mean weight, 89.2 kg) with a mean age of 42.9 years (range, 21-60 years) seen in a university-based weight management program.Structured aerobic exercise or moderate lifestyle activity; low-fat diet of about 1200 kcal/d.Changes in body weight, body composition, cardiovascular risk profiles, and physical fitness at 16 weeks and at 1 year.Mean (SD) weight losses during the 16-week treatment program were 8.3 (3.8) kg for the aerobic group and 7.9 (4.2) kg for the lifestyle group (within groups, P<.001; between groups, P = .08). The aerobic group lost significantly less fat-free mass (0.5 [1.3] kg) than the lifestyle group (1.4 [1.3] kg; P = .03). During the 1-year follow-up, the aerobic group regained 1.6 [5.5] kg, while the lifestyle group regained 0.08 (4.6) kg. At week 16, serum triglyceride levels and total cholesterol levels were reduced significantly (P<.001) from baseline (16.3% and 10.1% reductions, respectively) but did not differ significantly between groups and were not different from baseline or between groups at week 68.A program of diet plus lifestyle activity may offer similar health benefits and be a suitable alternative to diet plus structured aerobic activity for obese women.
Predictive value of venom‐specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom
Authors: U. MÜLLER, A. HELBLING, M. BISCHOF
Journal: Allergy (1989)

Sixty‐seven patients with a history of severe systemic reactions following honey bee stings were treated by immunotherapy (IT) with honey bee venom. During maintenance therapy all were submitted to a sting challenge under clinical conditions. 15 developed mostly minor symptoms of a systemic reaction while 52 showed only a local swelling at the sting site. Phospholipase A 2 ‐specific IgE, IgG and IgG subclass serum antibodies were estimated in samples obtained before IT and immediately before the challenge. Specific IgE decreased in reactors and in non‐reactors. There was no difference between the two groups at any time. Specific total IgG, IgG 1 and IgG 4 increased in both reactors and non‐reactors during IT. An early increase of specific IgG 1 , was observed while specific IgG 4 remained elevated throughout the treatment. Specific total IgG was higher in reactors than non‐reactors before the challenge, specific IgG 1 higher in reactors before treatment and specific IgG 4 higher in reactors than non‐reactors both before treatment and before challenge. In the individual patient, no single antibody estimation or combination of various antibodies was predictive of the outcome of a sting challenge.
Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects
Authors: J BAUERSACHS, K HISS, D FRACCAROLLO, U LAUFS, H RUETTEN
Journal: Cardiovascular Research (2006)

Objectives: Hypercholesterolemia contributes to coronary artery disease progression but little is known about its effect on left ventricular (LV) function after myocardial infarction (MI). The aim of this study was to investigate the effects of hypercholesterolemia and statin treatment in rabbits with experimental MI. Methods and results: New Zealand White rabbits on a normal or cholesterol-rich diet for 4 weeks, underwent permanent coronary artery ligation. Starting on the first day post-MI rabbits were treated with either placebo or simvastatin (5 mg/kg/day) for 9 weeks. Hypercholesterolemia itself did not affect LV function in sham-operated animals but further impaired LV systolic (dP/dtmax−42%) and diastolic (dP/dtmin−47%) function in MI rabbits on placebo. Simvastatin treatment not only prevented deterioration of LV function associated with hypercholesterolemia but improved LV function (dP/dtmax+130%; dP/dtmin+144%, P<0.05). Simvastatin also attenuated the depression of LV function in normocholesterolemic MI rabbits (dP/dtmax+46%;dP/dtmin+53%, P<0.05). Hypercholesterolemia in MI rabbits coincided with a significant increase in C-reactive protein levels (marker of inflammation) and Rac1-GTPase activity (marker of oxidative stress), and a reduction in cardiac sarcoplasmic-reticulum calcium ATPase-2 expression and endothelial nitric oxide synthase protein phosphorylation, all of which were normalised by simvastatin treatment. Elevated serum cholesterol levels were only partially reduced by simvastatin. Conclusions: Hypercholesterolemia further impaired the depressed LV function in rabbits post-MI. Statin treatment reversed this effect, and conferred additional protection, as in normocholesterolemic animals. Our study suggests that anti-inflammatory and anti-oxidative effects of simvastatin substantially contribute to its beneficial effects on cardiac function after MI.
Curability of Pulmonary Consumption: With Observations on its Treatment, and Cases Illustrating the Efficacy of Cod-Liver Oil
Authors: J. Turnbull
Journal: BMJ (1850)

Tymf examination of the question, how far Consumption is a curable disease, is a subject which has scarcely received from medical men the attention it deserves, when we consider the very general prevalence of this disease, and the amount of mortality it occasions.The profession, as well as the public, have been so strongly impressed with the belief that the disease is necessarily fatal, that any one who would have maintained the opposite opinion would, until very recently, have been looked upon only in the light of a boasting pretender.Notwithstanding this, pathological investigations have shown, in the clearest manner, that recovery often does tAke place from this disease; and ever since the able investigations of Laenne proved that this may occur from the spontaneous efforts of nature, subsequent pathologists have been accu- mulating facts, proving more fully the correctness of his views and statements.Auscultation and percussion, by enabling us to separate those diseases from Consumption which most nearly resemble it, and to trace the successive steps of recovery on living individuals, have com- pleted what was required, in order to establish the point.I believe that medical men are not generally aware of the amount of strong evi- dence that exists in reference to the curability of Phthisis; but I hope to bring forward in this paper a sufficient amount of facts to prove, that it admits of recovery in several ways, and that we should increase our efforts to save consumptive patients, having now, in cod-liver oil, at least one remedy which possesses an undoubted power over this destruc tive disease.Let us, before entering upon this subject, inquire, as briefly as pos- sible, what light has been thrown on the pathology of tubercle, and the changes it undergoes during absorption and transformation, by recent chemical and microsopical researches.As regards the blood itself, VOL.11.
Progestins Reinitiate Cell Cycle Progression in Antiestrogen-Arrested Breast Cancer Cells through the B-Isoform of Progesterone Receptor
Authors: Eileen M. McGowan, Amanda J. Russell, Viroj Boonyaratanakornkit, Darren N. Saunders, Gillian M. Lehrbach, C. Marcelo Sergio, Elizabeth A. Musgrove, Dean P. Edwards, Robert L. Sutherland
Journal: Cancer Research (2007)

Abstract Estrogen treatment of MCF-7 human breast cancer cells allows the reinitiation of synchronous cell cycle progression in antiestrogen-arrested cells. Here, we report that progestins also reinitiate cell cycle progression in this model. Using clonal cell lines derived from progesterone receptor (PR)–negative MCF-7M13 cells expressing wild-type or mutant forms of PRA and PRB, we show that this effect is mediated via PRB, not PRA. Cell cycle progression did not occur with a DNA-binding domain mutant of PRB but was unaffected by mutation in the NH2-terminal, SH3 domain interaction motif, which mediates rapid progestin activation of c-Src. Thus, the progestin-induced proliferative response in antiestrogen-inhibited cells is mediated primarily by the transcriptional activity of PRB. Analysis of selected cell cycle targets showed that progestin treatment induced levels of cyclin D1 expression and retinoblastoma protein (Rb) phosphorylation similar to those induced by estradiol. In contrast, progestin treatment resulted in only a 1.2-fold induction of c-Myc compared with a 10-fold induction by estradiol. These results support the conclusion that progestin, in a PRB-dependent manner, can overcome the growth-inhibitory effects of antiestrogens in estrogen receptor/PR-positive breast cancer cells by the induction of cyclin D1 expression. The mediation of this effect by PRB, but not PRA, further suggests a mechanism whereby abnormal regulation of the normal expression ratios of PR isoforms in breast cancer could lead to the attenuation of antiestrogen-mediated growth arrest. [Cancer Res 2007;67(18):8942–51]
A case of naevus lipomatosus cutaneus superficialis of the scalp associated with pedunculated basal cell carcinoma
Authors: A. Maeda, Y. Aragane, K. Ueno, F. Yamazaki, A. Kawada, T. Tezuka
Journal: British Journal of Dermatology (2003)

Journal Article A case of naevus lipomatosus cutaneus superficialis of the scalp associated with pedunculated basal cell carcinoma Get access A. Maeda, A. Maeda Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar Y. Aragane, Y. Aragane Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Yoshinori Aragane Search for other works by this author on: Oxford Academic Google Scholar K. Ueno, K. Ueno Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar F. Yamazaki, F. Yamazaki Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar A. Kawada, A. Kawada Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar T. Tezuka T. Tezuka Department of Dermatology, Kinki University School of Medicine, Osakasayama, Japan E‐mail: nori@kindai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 148, Issue 5, 1 May 2003, Pages 1084–1086, https://doi.org/10.1046/j.1365-2133.2003.05196.x Published: 01 May 2003
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study
Authors: I Hafström, K Albertsson, A Boonen, D van der Heijde, R Landewé, B Svensson
Journal: Annals of the Rheumatic Diseases (2008)

Objective: To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years. Methods: A total of 150 of 211 eligible patients with RA who had been randomised to the 7.5 mg prednisolone group (P) or no prednisolone group (NoP) in addition to the initial disease-modifying antirheumatic drugs were included. Radiographs of hands and feet were scored using the Sharp–van der Heijde scoring method. A patient was considered to be in remission if the 28-joint count disease activity score was &lt;2.6. Results: Mean (SD) age was 53 (14) and 57 (12) years for the patients in the P and NoP groups, respectively. 64% were female, 64% rheumatoid factor positive, and disease duration at baseline was 6 months. At 2 years the proportion of patients in remission in the P and NoP groups was 55 vs 30%, p = 0.003. Longitudinal analysis showed that over the entire course of the disease, patients on prednisolone had a higher probability of being in remission. Patients in remission at 2 years, compared with those not in remission, had significantly lower total Sharp score, erosion score and joint space narrowing score at 2 and 4 years. The changes in bone mineral density during the 4 years did not differ between those in remission and those with active disease, and were similar in the two treatment groups. Conclusions: Prednisolone 7.5 mg daily in addition to disease-modifying anti-rheumatic drugs increases the rate of remission in patients with early RA, which has a beneficial and sustained effect on radiological damage.
292 A RANDOMIZED PILOT TRIAL OF ORAL BRANCHED-CHAIN AMINO ACIDS IN EARLY LIVER CIRRHOSIS
Authors: E. Kawamura, D. Habu, S. Iwai, H. Morikawa, M. Enomoto, A. Tamori, H. Sakaguchi, N. Kawada, S. Shiomi
Journal: Journal of Hepatology (2008)
A COMPARISON OF PERPHENAZINE, PROKETAZINE, NIALAMIDE AND MO-482 IN CHRONIC SCHIZOPHRENICS
Authors: NAUTTAM J. KOTHARI, JOHN C. SAUNDERS, NATHAN S. KLINE, JOSEPH A. GRIFFEN
Journal: American Journal of Psychiatry (1960)

Of 25 chronic schizophrenics in each group on perphenazine and proketazine, 11 patients on each drug showed improvement. The patients with delusions, hallucinations and hyperactivity had the maximal benefit from these psychoinhibiting drugs. Of 25 chronic schizophrenics in each group, 11 improved with nialamide and 7 with MO-482. Seven patients on perphenazine and 8 on proketazine improved either to a moderate or marked degree. Moderate to marked improvement was seen in 3 and 5 patients on nialamide and MO-482 respectively. Apathetic and autistic patients had the maximal benefit from the psychoactivating drugs. These drugs are relatively safe as no serious untoward clinical or laboratory results were observed.
Abstract LB-284: Combination of antiandrogens and PI3-kinase pathway inhibitors in a model of androgen-dependent prostate cancer
Authors: Clay Efferson, Joe Zhu, Chris Ware, Jennifer Tammam, Minilik Angagaw, John F. Reilly, Cyrille Sur, Edwin Clark, Chris Winter, Weisheng Zhang, Pradip K. Majumder
Journal: Cancer Research (2010)

Abstract Prostate cancer is the third most common cause of cancer-related deaths in men and is most prevalent in developed countries. The androgen signaling pathway plays a critical role in the development and maintenance of the prostate gland and is hyper-activated in prostate cancer. Additionally, gain of function mutations in the PI3 kinase pathway is associated with progression of this disease. Using the prostate-specific Pten-deleted mouse model of cancer, we show that these two pathways are distinct for tumor growth and disease progression. Depletion of androgens by either surgical or chemical castration significantly inhibits tumor growth without altering the activation of Akt and mTOR. We demonstrate that inhibition of mTOR with ridaforolimus or inhibition of Akt with MK-2206, combined with androgen deprivation (bicalutamide), results in additive anti-tumor effects in vivo when compared to single agent treatment. In this model, we also demonstrate that Akt inhibition does not block mTOR kinase activation, and that inhibiting both Akt and mTOR kinases together significantly enhances anti-tumor efficacy. Our data suggest that the combination of an anti-androgen with an mTOR inhibitor and/or Akt inhibitor may be more effective than standard therapies in treating androgen-dependent prostate cancer patients with an activated PI3 kinase pathway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-284.
Histochemical detection of specific isozymes of myosin in rat ventricular cells.
Authors: A Weisberg, S Winegrad, M Tucker, G McClellan
Journal: Circulation Research (1982)

A histochemical method for distinguishing isozymes of myosin in rat ventricles has been developed. The procedure involves preincubation in pH 10.5, which inhibits Ca-activated ATPase of the V3 isozyme but not the V1 isozyme of myosin. The specificity of the technique has been demonstrated by comparison of results in hearts from young euthyroid and hypothyroid rats, in which the predominant isozymes are, respectively, V1 and V3. The technique is capable of detecting as small a change in the relative amount of V1 as 15% of the total myosin. Isoenzymes appear to be uniformly distributed within each ventricular cell. There is only a small difference in the content of V1 among the cells in a ventricular chamber of hearts from young euthyroid and hypothyroid rats, but in the period of rapid transition of isozyme content after thyroidectomy, there is considerable heterogeneity of V1 concentration among the cells. The functional implications of the mixture of isozymes is discussed.
Ginkgo and Memory
Authors: Klaus R. Arnold
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biliary Scintigraphy
Authors: MICHAEL A. CAWTHON, DEBRA M. BROWN, MICHAEL F. HARTSHORNE, ROBERT D. KARL, JOHN M. BAUMAN, WILLIAM H. HOWARD, STEPHEN R. BUNKER
Journal: Clinical Nuclear Medicine (1984)

A new cholescintigraphic finding, the "hot rim" sign, is reported in a case of acute cholecystitis. Local inflammation in the gallbladder fossa may be the cause of this phenomenon.